

(Rac)-HAMI 3379

Chemical Properties


CAS No. : 712313-35-4

Formula: C₃₄H₄₅N₀O₈

Molecular Weight: 595.72

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	HAMI 3379 is a potent and selective antagonist of the Cysteinyl leukotriene (CysLT2) receptor. HAMI 3379 has a protective effect on acute and subacute ischemic brain injury. It also attenuates microglia-related inflammation.
Targets(IC50)	Others,Leukotriene Receptor
In vitro	HAMI 3379 shows very low potency on a recombinant CysLT1 receptor cell line (IC50>10000 nM). HAMI 3379 antagonizes leukotriene D4- (LTD4-) and leukotriene C4- (LTC4-) induced intracellular calcium mobilization (IC50: 3.8 nM and 4.4 nM, respectively), in a CysLT2 receptor reporter cell line[1].
In vivo	HAMI 3379 (infused into the aortic cannula at a rate of 1% of the total flow rate; 0.01, 0.1, 1 μM; 20 min) concentration-dependently inhibits and reverses the LTC4-induced perfusion pressure increase and contractility decrease[1]. HAMI 3379 (ip; 0.025-0.4 mg/kg; 24 hours) decreases the acute brain injury 24 hours after middle cerebral artery occlusion (MCAO) with effective doses of 0.1-0.4 mg/kg and a therapeutic window of ~ 1 hour. It reduces neurological deficits and reduces infarct volume, brain edema, and neuronal loss and degeneration 24 and 72 hours after MCAO[2].

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.6786 mL	8.3932 mL	16.7864 mL
5 mM	0.3357 mL	1.6786 mL	3.3573 mL
10 mM	0.1679 mL	0.8393 mL	1.6786 mL
50 mM	0.0336 mL	0.1679 mL	0.3357 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Wunder F, et al. Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT₂) receptor. Br J Pharmacol. 2010 May;160(2):399-409.

Zhang XY, et al. HAMI 3379, a CysLT₂ receptor antagonist, attenuates ischemia-like neuronal injury by inhibiting microglial activation. J Pharmacol Exp Ther. 2013 Aug;346(2):328-41.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481